AHARA Mushrooms Publishes Comprehensive Metabolomic Analysis of Reishi Supplement

Maryland biotech startup reveals first-of-its-kind data from independent metabolomics laboratory

Published on Feb. 21, 2026

Got story updates? Submit your updates here. ›

AHARA Mushrooms, a Rockville, Maryland-based biotech company, has published the results of the most comprehensive metabolomic analysis ever conducted on a mushroom supplement. The analysis, performed by a leading metabolomics laboratory, revealed over 1,000 uniquely identified compounds in AHARA's proprietary Reishi extract, including adenosine precursors, GABA, glycine, oleamide, ganoderic acids, short-chain fatty acids, and bioactive peptides.

Why it matters

This analysis provides unprecedented insight into the full spectrum of bioactive compounds present in AHARA's Reishi supplement, which could have significant implications for understanding the potential health benefits of Reishi mushrooms. The company's proprietary water-based extraction process also represents a breakthrough in the mushroom industry, as it is able to recover a wide range of compounds without the use of harsh organic solvents.

The details

The metabolomic analysis, conducted using dual-panel CE-MS and LC-MS mass spectrometry, revealed that AHARA's Reishi extract contains compounds spanning 17 distinct metabolic pathways, including those related to sleep, mood, inflammation, and gut-brain axis signaling. Key compounds identified include adenosine precursors, GABA, glycine, oleamide, 26 ganoderic acids, 35 short-chain fatty acids, and 27 bioactive peptides. AHARA's proprietary water-based extraction process was able to recover these compounds without the use of ethanol or methanol, preserving the full spectrum of bioactives in a single aqueous extract.

  • The metabolomic analysis was published on February 18, 2026.

The players

AHARA Mushrooms

A Rockville, Maryland-based biotech company developing scientifically validated mushroom therapeutics.

Dr. Subhas Malghan

The co-founder of AHARA Mushrooms and co-author of the FDA's first nanotechnology guidance.

Aaron Grimes

The co-founder of AHARA Mushrooms with an MBA.

Got photos? Submit your photos here. ›

What they’re saying

“Every step of our process is American. We grow and extract our mushrooms in the U.S, and validate our products at a globally recognized metabolomics laboratory. We're not just importing extracts and slapping a label, we control the supply chain and the science.”

— Aaron Grimes, Co-founder, AHARA Mushrooms (PRNewswire)

The takeaway

AHARA's comprehensive metabolomic analysis of its Reishi supplement provides unprecedented insight into the full spectrum of bioactive compounds present in the product, which could have significant implications for understanding the potential health benefits of Reishi mushrooms. The company's proprietary water-based extraction process also represents a breakthrough in the mushroom industry, as it is able to recover a wide range of compounds without the use of harsh organic solvents.